Abpro Holdings, Inc.

Abpro Holdings, Inc. (Nasdaq: ACAB) is a clinical-stage biopharmaceutical company focused on the discovery and development of antibody-based therapeutics. The company, which operates in the biotechnology and life sciences sector, filed an 8-K with the Securities and Exchange Commission on November 26, 2024, disclosing a material corporate event. Abpro reached public markets through a SPAC transaction and has since traded on Nasdaq under the ACAB ticker. The biopharmaceutical sector has been an active area for SPAC activity, with development-stage companies leveraging blank-check vehicles to access public capital markets. For the full filing history, sponsor details, and real-time status updates on ACAB and hundreds of other SPAC-related securities, sign up for a SpacDesk account at spacdesk.com.